Short androgenic suppression and high dose radiotherapy (80 Gy) for prostate cancer with intermediate risk: interim analysis of randomized trial 14 by the Group of uro-genital tumour investigations (Getug)

The authors report an interim analysis of a randomized trial for the assessment of the contribution of a short androgenic suppression to a high-dose irradiation on patients suffering from an intermediate risk localized prostate cancer. The study concerned a bit less than 400 patients treated between 2003 and 2010. About half of them had hormonotherapy, and the other half not. Results are discussed in terms of biochemical or clinical control probability, of cumulative grade-3 and grade-4 toxicity rates. The benefit of androgenic suppression does not reach a statistic significant threshold. Short communication